-
PhaseBio Analyst Says Coronavirus Study Creates Near-Term Catalyst
Thursday, May 28, 2020 - 11:10am | 383Read More...PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) shares were skyrocketing Thursday after the company revealed it has received the go-ahead from the FDA for evaluating one of its lead assets for COVID-19 in clinics. The PhaseBio Analyst Stifel analyst Adam Walsh has a Buy rating on PhaseBio with a...
-
What Analysts Have To Say About Insmed Following Arikayce Approval
Monday, October 1, 2018 - 6:01pm | 398Read More...Insmed Incorporated (NASDAQ: INSM) stock crashed Monday after the U.S. Food & Drug Administration approved the company’s antibiotic Arikayce. In addition to “sell the news” traders moving on following the FDA approval, some sellers are likely concerned about the revelation...
-
Galmed Notches Second Bullish Rating On Aramchol Opportunity
Friday, July 13, 2018 - 10:49am | 446Read More...Two days after Cantor Fitzgerald gave Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) a shot in the arm with an ultrabullish rating, Stifel Nicolaus administered a booster. Galmed spiked 15 percent Friday morning after already having risen 21 percent in the preceding session. The Analyst ...
-
Ascendis Will Rise Higher On 'Game-Changing' TransCon Technology, Stifel Says In Bullish Initiation
Tuesday, June 26, 2018 - 10:21am | 407Read More...Ascendis Pharma A/S (NASDAQ: ASND) shares are up 180 percent year-over-year, but one analyst thinks the Street hasn’t been generous enough. The Analyst Stifel Nicolaus analyst Adam Walsh initiated coverage on Ascendis with a Buy rating and $85 price target. The Thesis By Walsh...
-
Corcept Therapeutics Is 'Fairly Valued,' Stifel Says In Downgrade
Thursday, May 31, 2018 - 12:52pm | 381Read More...Stifel's bullish case for Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company that focuses on drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, no longer applies. The Analyst Stifel's Adam Walsh downgraded...
-
Protagonist Therapeutics 'Poised For Upside,' Stifel Says
Monday, January 29, 2018 - 1:14pm | 405Read More...Protagonist Therapeutics Inc (NASDAQ: PTGX) has been central to the portfolios of three Street analysts. Now it's taking a leading role with Stifel Nicolaus. The Rating Stifel analyst Adam Walsh initiated coverage on Protagonist with a Buy rating and $32 price target. The Thesis Two oral...
-
Weakness In Corcept Shares Is 'Overdone,' According To Analyst
Tuesday, October 10, 2017 - 4:01pm | 322Read More...Corcept Therapeurtics Incorporated (NASDAQ: CORT) shares are down more than 7 percent Tuesday after the company seemingly reported a steep decline in Korlym prescriptions. However, the stock is bouncing off its lows on what Stifel analyst Adam Walsh says is a simple misunderstanding. According to...
-
Stifel: Buy Vetrex, Checks Predict Strong Orkambi Launch
Tuesday, December 1, 2015 - 10:45am | 322Read More...Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) are up 9 percent year-to-date, but slipped below the $100 mark in September. Stifel’s Adam Walsh initiated coverage of the company with a Buy rating and a price target of $160. The company’s growth is expected to be...
-
What's The Street Think Of Alnylam Pharmaceuticals New Drug Data?
Wednesday, June 24, 2015 - 3:49pm | 287Read More...Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s sell-off is unrelated to data the company presented late Tuesday for its prospective hemophilia treatment, an analyst said. Deutsche Bank's Alethia Young attributed the decline to "fast money, selling," and has previously...
-
Here's What Canaccord Learned After Spending A Day With Synageva's Management
Thursday, May 7, 2015 - 3:30pm | 280Read More...In a report published Thursday, Canaccord Genuity analyst Adam Walsh, MD detailed a recent meeting with Synageva Biopharma Corp (NASDAQ: GEVA)'s management team and came away "more positive" on the LAL-D commercial opportunity. Separately, Synageva has announced that Alexion Pharmaceuticals, Inc. (...
